Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Carcinoma, Hepatocellular 9Nasopharyngeal Carcinoma 7Esophageal Neoplasms 6Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Melanoma 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Leukemia, Myeloid, Acute 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Temozolomide 7Vincristine 6Cyclophosphamide 5fludarabine 3Irinotecan 3pegfilgrastim 2irinotecan sucrosofate 2Zoledronic Acid 2Vinorelbine 2Filgrastim 2Dactinomycin 2talazoparib 1silmitasertib 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pazopanib 1liposomal doxorubicin 1fludarabine phosphate 1cabozantinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Radiotherapy 1Mesna 1Melphalan 1Influenza Vaccines 1Indocyanine Green 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Rhabdomyosarcoma × Immune Checkpoint Inhibitors × Clear all
NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

Phase 1 Recruiting
25 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡